Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hyperlipoproteinemias

  Free Subscription


Articles published in Atherosclerosis

Retrieve available abstracts of 337 articles:
HTML format



Single Articles


    June 2021
  1. MALO AI, Girona J, Ibarretxe D, Rodriguez-Borjabad C, et al
    Serum glycoproteins A and B assessed by (1)H-NMR in familial hypercholesterolemia.
    Atherosclerosis. 2021;330:1-7.
    PubMed     Abstract available


  2. PAQUETTE M, Fantino M, Bernard S, Baass A, et al
    Paternal inheritance predicts earlier cardiovascular event onset in patients with familial hypercholesterolemia.
    Atherosclerosis. 2021;329:9-13.
    PubMed     Abstract available


  3. ROOS CM, Zhang B, Hagler MA, Arghami A, et al
    MnSOD protects against vascular calcification independent of changes in vascular function in hypercholesterolemic mice.
    Atherosclerosis. 2021 Jun 8. pii: S0021-9150(21)00276.
    PubMed     Abstract available


    May 2021
  4. REESKAMP LF, Nurmohamed NS, Bom MJ, Planken RN, et al
    Marked plaque regression in homozygous familial hypercholesterolemia.
    Atherosclerosis. 2021;327:13-17.
    PubMed     Abstract available


    April 2021
  5. BRANDTS J, Dharmayat KI, Vallejo-Vaz AJ, Azar Sharabiani MT, et al
    A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia.
    Atherosclerosis. 2021;325:46-56.
    PubMed     Abstract available


  6. INGOE L, Potter A, Musson S, Neely D, et al
    Improving the identification of patients with a genetic diagnosis of familial hypercholesterolaemia in primary care: A strategy to achieve the NHS long term plan.
    Atherosclerosis. 2021;325:38-45.
    PubMed     Abstract available


  7. SUADONI MT
    Benefits and harms of LDL-cholesterol-lowering therapy in older people must be established through valid and clinically relevant evidence.
    Atherosclerosis. 2021;323:57-58.
    PubMed    


  8. LIMA JG, Helena C Nobrega L, Moura Bandeira FT, Pires Sousa AG, et al
    A novel GPIHBP1 mutation related to familial chylomicronemia syndrome: A series of cases.
    Atherosclerosis. 2021;322:31-38.
    PubMed     Abstract available


  9. JO SH, Han SH, Kim SH, Eckel RH, et al
    Cardiovascular effects of omega-3 fatty acids: Hope or hype?
    Atherosclerosis. 2021;322:15-23.
    PubMed     Abstract available


    March 2021
  10. BUONUOMO PS, Mastrogiorgio G, Leone G, Rana I, et al
    Evolocumab in the management of children <10 years of age affected by homozygous familial hypercholesterolemia.
    Atherosclerosis. 2021 Mar 28. pii: S0021-9150(21)00147.
    PubMed    


  11. ELLINS EA, Watkins S, Rees DA, Datta DBN, et al
    Acute effect of a single session of lipoprotein apheresis on central haemodynamics in patients with familial hypercholesterolaemia.
    Atherosclerosis. 2021 Mar 27. pii: S0021-9150(21)00144.
    PubMed    


  12. BIESECKER LG
    Correspondence on: "Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features".
    Atherosclerosis. 2021 Mar 20. pii: S0021-9150(21)00125.
    PubMed    


  13. ZIGMOND ZM, Song L, Martinez L, Lassance-Soares RM, et al
    c-Kit expression in smooth muscle cells reduces atherosclerosis burden in hyperlipidemic mice.
    Atherosclerosis. 2021 Mar 9. pii: S0021-9150(21)00112.
    PubMed     Abstract available


  14. BANACH M, Penson PE
    Lipid-lowering therapies: Better together.
    Atherosclerosis. 2021;320:86-88.
    PubMed    


    February 2021
  15. LEREN TP, Bogsrud MP
    Molecular genetic testing for autosomal dominant hypercholesterolemia in 29,449 Norwegian index patients and 14,230 relatives during the years 1993-2020.
    Atherosclerosis. 2021;322:61-66.
    PubMed     Abstract available


  16. REESKAMP LF, Balvers M, Peter J, van de Kerkhof L, et al
    Intronic variant screening with targeted next-generation sequencing reveals first pseudoexon in LDLR in familial hypercholesterolemia.
    Atherosclerosis. 2021;321:14-20.
    PubMed     Abstract available


    January 2021
  17. VUORIO A, Raal F, Kaste M, Kovanen PT, et al
    Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment.
    Atherosclerosis. 2021;320:53-60.
    PubMed     Abstract available


  18. MARCO-BENEDI V, Laclaustra M, Bea AM, Suarez-Tembra M, et al
    Maternally inherited hypercholesterolemia does not modify the cardiovascular phenotype in familial hypercholesterolemia.
    Atherosclerosis. 2021;320:47-52.
    PubMed     Abstract available


  19. FUTEMA M, Ramaswami U, Tichy L, Bogsrud MP, et al
    Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries.
    Atherosclerosis. 2021;319:108-117.
    PubMed     Abstract available


  20. GAUTIER T, Deckert V, Aires V, Le Guern N, et al
    Human apolipoprotein C1 transgenesis reduces atherogenesis in hypercholesterolemic rabbits.
    Atherosclerosis. 2021;320:10-18.
    PubMed     Abstract available


  21. VALLEJO-VAZ AJ, Packard CJ, Ference BA, Santos RD, et al
    LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial.
    Atherosclerosis. 2021;320:1-9.
    PubMed     Abstract available


  22. KOROSOGLOU G, Chatzizisis YS, Raggi P
    Coronary computed tomography angiography in asymptomatic patients: Still a taboo or precision medicine?
    Atherosclerosis. 2021;317:47-49.
    PubMed    


  23. STOCK JK
    Should we treat high LDL cholesterol in 'healthy' elderly individuals?
    Atherosclerosis. 2021;317:50-51.
    PubMed    


    December 2020
  24. RUBINO J, MacDougall DE, Sterling LR, Hanselman JC, et al
    Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial.
    Atherosclerosis. 2020 Dec 31. pii: S0021-9150(20)31597.
    PubMed     Abstract available


  25. SVENDSEN K, Krogh HW, Igland J, Tell GS, et al
    2.5-fold increased risk of recurrent acute myocardial infarction with familial hypercholesterolemia.
    Atherosclerosis. 2020;319:28-34.
    PubMed     Abstract available


  26. COUTINHO ER, Miname MH, Rocha VZ, Bittencourt MS, et al
    Familial hypercholesterolemia and cardiovascular disease in older individuals.
    Atherosclerosis. 2020;318:32-37.
    PubMed     Abstract available


  27. SVENDSEN K, Langslet G, Krogh HW, Brinck J, et al
    Genetic testing is essential for initiating statin therapy in children with familial hypercholesterolemia: Examples from Scandinavia.
    Atherosclerosis. 2020;316:48-52.
    PubMed     Abstract available


    November 2020
  28. REESKAMP LF, Tromp TR, Huijgen R, Stroes ESG, et al
    Statin therapy reduces plasma angiopoietin-like 3 (ANGPTL3) concentrations in hypercholesterolemic patients via reduced liver X receptor (LXR) activation.
    Atherosclerosis. 2020;315:68-75.
    PubMed     Abstract available


  29. PEREZ DE ISLA L, Alonso R, Gomez de Diego JJ, Muniz-Grijalvo O, et al
    Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia: A computed tomographic angiography study.
    Atherosclerosis. 2020 Nov 18. pii: S0021-9150(20)31521.
    PubMed     Abstract available


    October 2020
  30. IYEN B, Qureshi N, Weng S, Roderick P, et al
    Sex differences in cardiovascular morbidity associated with familial hypercholesterolaemia: A retrospective cohort study of the UK Simon Broome register linked to national hospital records.
    Atherosclerosis. 2020 Oct 31. pii: S0021-9150(20)31491.
    PubMed     Abstract available


    September 2020
  31. BURRIS RL, Vick SC, Popovic B, Fraungruber PE, et al
    Maternal exposure to soy diet reduces atheroma in hyperlipidemic F1 offspring mice by promoting macrophage and T cell anti-inflammatory responses.
    Atherosclerosis. 2020;313:26-34.
    PubMed     Abstract available


  32. IQBAL Z, Ho JH, Adam S, France M, et al
    Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK.
    Atherosclerosis. 2020;313:126-136.
    PubMed     Abstract available


  33. BERTOLINI S, Calandra S, Arca M, Averna M, et al
    Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features.
    Atherosclerosis. 2020;312:72-78.
    PubMed     Abstract available


    August 2020
  34. MULORZ J, Spin JM, Beck HC, Tha Thi ML, et al
    Hyperlipidemia does not affect development of elastase-induced abdominal aortic aneurysm in mice.
    Atherosclerosis. 2020;311:73-83.
    PubMed     Abstract available


  35. RODRIGUEZ-NOVOA S, Rodriguez-Jimenez C, Alonso C, Rodriguez-Laguna L, et al
    Familial hypercholesterolemia: A single-nucleotide variant (SNV) in mosaic at the low density lipoprotein receptor (LDLR).
    Atherosclerosis. 2020;311:37-43.
    PubMed     Abstract available


  36. PEPPLINKHUIZEN S, Ibrahim S, Vink R, Groot B, et al
    Electronic health records to facilitate continuous detection of familial hypercholesterolemia.
    Atherosclerosis. 2020;310:83-87.
    PubMed     Abstract available


  37. ALJENEDIL S, Alothman L, Belanger AM, Brown L, et al
    Lomitapide for treatment of homozygous familial hypercholesterolemia: The Quebec experience.
    Atherosclerosis. 2020;310:54-63.
    PubMed     Abstract available


    July 2020
  38. RALLIDIS LS, Liberopoulos EN, Vlachopoulos C, Skoumas I, et al
    Very high-risk familial hypercholesterolaemia patients in real life: The remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitors.
    Atherosclerosis. 2020 Jul 30. pii: S0021-9150(20)30385.
    PubMed    


  39. PASTA A, Cremonini AL, Formisano E, Fresa R, et al
    Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies.
    Atherosclerosis. 2020;308:6-14.
    PubMed     Abstract available


  40. GULIZIA MM, Maggioni AP, Abrignani MG, Bilato C, et al
    Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease: The POSTER study.
    Atherosclerosis. 2020;308:32-38.
    PubMed     Abstract available


  41. FUKUMOTO K, Takemoto Y, Yoshikawa J, Norioka N, et al
    Predictors of endothelial function improvement in patients with mild hypertriglyceridemia without evidence of coronary artery disease treated with purified eicosapentaenoic acid.
    Atherosclerosis. 2020;309:27-32.
    PubMed     Abstract available


  42. STOCK J
    Familial hypercholesterolemia: An urgent public health priority.
    Atherosclerosis. 2020 Jul 18. pii: S0021-9150(20)30351.
    PubMed    


  43. GALLO A, Charriere S, Vimont A, Chapman MJ, et al
    SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia.
    Atherosclerosis. 2020;306:41-49.
    PubMed     Abstract available


    May 2020
  44. LAU P, Soubeyrand S, Hegele RA, Lagace TA, et al
    Molecular mechanism linking a novel PCSK9 copy number variant to severe hypercholesterolemia.
    Atherosclerosis. 2020;304:39-43.
    PubMed     Abstract available


  45. STOCK JK
    Homozygous familial hypercholesterolaemia: New hope for getting patients to goal?
    Atherosclerosis. 2020 May 25. pii: S0021-9150(20)30230.
    PubMed    


  46. ADEMI Z, Norman R, Pang J, Liew D, et al
    Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?
    Atherosclerosis. 2020;304:1-8.
    PubMed     Abstract available


  47. TSIMIKAS S, Stroes ESG
    The dedicated "Lp(a) clinic": A concept whose time has arrived?
    Atherosclerosis. 2020;300:1-9.
    PubMed     Abstract available


  48. DE NISCO G, Hoogendoorn A, Chiastra C, Gallo D, et al
    The impact of helical flow on coronary atherosclerotic plaque development.
    Atherosclerosis. 2020;300:39-46.
    PubMed     Abstract available


    March 2020
  49. PANG J, Abraham A, Vargas-Garcia C, Bates TR, et al
    An age-matched computed tomography angiographic study of coronary atherosclerotic plaques in patients with familial hypercholesterolaemia.
    Atherosclerosis. 2020;298:52-57.
    PubMed     Abstract available


  50. ADINOLFI LE, Petta S, Fracanzani AL, Coppola C, et al
    Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study.
    Atherosclerosis. 2020;296:40-47.
    PubMed     Abstract available


    February 2020
  51. LUIRINK IK, Hutten BA, Greber-Platzer S, Kolovou GD, et al
    Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry.
    Atherosclerosis. 2020;299:24-31.
    PubMed     Abstract available


  52. NORDESTGAARD BG, Langlois MR, Langsted A, Chapman MJ, et al
    Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM.
    Atherosclerosis. 2020;294:46-61.
    PubMed     Abstract available


    January 2020
  53. CHIU YW, Wu CS, Chen PC, Wei YC, et al
    Risk of acute mesenteric ischemia in patients with diabetes: A population-based cohort study in Taiwan.
    Atherosclerosis. 2020;296:18-24.
    PubMed     Abstract available


    December 2019
  54. FULLER DT, Grainger AT, Manichaikul A, Shi W, et al
    Genetic linkage of oxidative stress with cardiometabolic traits in an intercross derived from hyperlipidemic mouse strains.
    Atherosclerosis. 2019;293:1-10.
    PubMed     Abstract available


    November 2019
  55. MULDER JWCM, Galema-Boers AMH, de Jong-Verweij LM, Hazelzet JA, et al
    The development and first results of a health-related outcomes set in familial hypercholesterolemia (FH) patients: Knowledge is health.
    Atherosclerosis. 2019;293:11-17.
    PubMed     Abstract available


  56. LAMIQUIZ-MONEO I, Restrepo-Cordoba MA, Mateo-Gallego R, Bea AM, et al
    Predicted pathogenic mutations in STAP1 are not associated with clinically defined familial hypercholesterolemia.
    Atherosclerosis. 2019;292:143-151.
    PubMed     Abstract available


  57. WALD DS, Bestwick JP
    Reaching detection targets in familial hypercholesterolaemia: Comparison of identification strategies.
    Atherosclerosis. 2019;293:57-61.
    PubMed     Abstract available


  58. RAMASWAMI U, Futema M, Bogsrud MP, Holven KB, et al
    Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries.
    Atherosclerosis. 2019;292:178-187.
    PubMed     Abstract available


    October 2019
  59. RAMOS R, Masana L, Comas-Cufi M, Garcia-Gil M, et al
    Derivation and validation of SIDIAP-FHP score: A new risk model predicting cardiovascular disease in familial hypercholesterolemia phenotype.
    Atherosclerosis. 2019;292:42-51.
    PubMed     Abstract available


  60. CAO YX, Jin JL, Guo YL, Sun D, et al
    Baseline and on-statin treatment lipoprotein(a) levels for predicting cardiovascular events in patients with familial hypercholesterolemia.
    Atherosclerosis. 2019;291:27-33.
    PubMed     Abstract available


    September 2019
  61. STOCK J
    First insights from the EAS familial hypercholesterolaemia collaboration registry: FH is still underdiagnosed and undertreated.
    Atherosclerosis. 2019 Sep 28. pii: S0021-9150(19)31502.
    PubMed    


  62. LEON-ACUNA A, Torres-Pena JD, Alcala-Diaz JF, Vals-Delgado C, et al
    Lifestyle factors modulate postprandial hypertriglyceridemia: From the CORDIOPREV study.
    Atherosclerosis. 2019;290:118-124.
    PubMed     Abstract available


  63. NAGARAJAN UM, Sikes JD, Burris RL, Jha R, et al
    Genital Chlamydia infection in hyperlipidemic mouse models exacerbates atherosclerosis.
    Atherosclerosis. 2019;290:103-110.
    PubMed     Abstract available


  64. RAMASWAMI U, Humphries SE, Priestley-Barnham L, Green P, et al
    Current management of children and young people with heterozygous familial hypercholesterolaemia - HEART UK statement of care.
    Atherosclerosis. 2019;290:1-8.
    PubMed     Abstract available


    August 2019
  65. DESJARLAIS M, Dussault S, Rivard F, Harel S, et al
    Forced expression of microRNA-146b reduces TRAF6-dependent inflammation and improves ischemia-induced neovascularization in hypercholesterolemic conditions.
    Atherosclerosis. 2019;289:73-84.
    PubMed     Abstract available


  66. HORI M, Ohta N, Takahashi A, Masuda H, et al
    Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients.
    Atherosclerosis. 2019;289:101-108.
    PubMed     Abstract available


  67. DUELL PB, Gidding SS, Andersen RL, Knickelbine T, et al
    Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry.
    Atherosclerosis. 2019;289:85-93.
    PubMed     Abstract available


    July 2019
  68. LANGSTED A, Vedel-Krogh S, Kobylecki CJ, Nordestgaard BG, et al
    Reply to: "Seasonal variations of lipid profiles in a French cohort".
    Atherosclerosis. 2019;286:184-186.
    PubMed    


  69. NADIF R, Goldberg S, Gourmelen J, Ozguler A, et al
    Seasonal variations of lipid profiles in a French cohort.
    Atherosclerosis. 2019;286:181-183.
    PubMed    


    June 2019
  70. MASANA L, Ibarretxe D, Rodriguez-Borjabad C, Plana N, et al
    Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain.
    Atherosclerosis. 2019;287:89-92.
    PubMed     Abstract available


  71. DYRBUS K, Gasior M, Desperak P, Osadnik T, et al
    The prevalence and management of familial hypercholesterolemia in patients with acute coronary syndrome in the Polish tertiary centre: Results from the TERCET registry with 19,781 individuals.
    Atherosclerosis. 2019;288:33-41.
    PubMed     Abstract available


  72. WISLOFF T, Mundal LJ, Retterstol K, Igland J, et al
    Economic evaluation of lipid lowering with PCSK9 inhibitors in patients with familial hypercholesterolemia: Methodological aspects.
    Atherosclerosis. 2019;287:140-146.
    PubMed     Abstract available


    May 2019
  73. IYEN B, Qureshi N, Kai J, Akyea RK, et al
    Risk of cardiovascular disease outcomes in primary care subjects with familial hypercholesterolaemia: A cohort study.
    Atherosclerosis. 2019;287:8-15.
    PubMed     Abstract available


  74. PEREZ DE ISLA L, Ray KK, Watts GF, Santos RD, et al
    Potential utility of the SAFEHEART risk equation for rationalising the use of PCSK9 monoclonal antibodies in adults with heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2019;286:40-45.
    PubMed     Abstract available


    April 2019
  75. LUIRINK IK, Kuipers IM, Hutten BA, Planken RN, et al
    Coronary computed tomography angiography and echocardiography in children with homozygous familial hypercholesterolemia.
    Atherosclerosis. 2019;285:87-92.
    PubMed     Abstract available


  76. ALOTHMAN L, Genest J
    Chylomicrons: When you can't direct the wind, adjust the sail.
    Atherosclerosis. 2019;283:121-123.
    PubMed    


    March 2019
  77. MIRAMONTES-GONZALEZ JP, Usategui-Martin R, Perez de Isla L, Alonso R, et al
    VEGFR2 and OPG genes modify the risk of subclinical coronary atherosclerosis in patients with familial hypercholesterolemia.
    Atherosclerosis. 2019;285:17-22.
    PubMed     Abstract available


  78. HARADA-SHIBA M
    How much further do we need to decrease LDL cholesterol levels in heterozygous familial hypercholesterolemia?
    Atherosclerosis. 2019 Mar 9. pii: S0021-9150(19)30121.
    PubMed    


    February 2019
  79. SHIOMI M, Takeda H, Irino Y, Kimura N, et al
    Identification of novel serum markers for the progression of coronary atherosclerosis in WHHLMI rabbits, an animal model of familial hypercholesterolemia.
    Atherosclerosis. 2019;284:18-23.
    PubMed     Abstract available


  80. CHEMELLO K, Martin C, Lambert G
    PCSK9 inhibition for autosomal recessive hypercholesterolemia.
    Atherosclerosis. 2019 Feb 23. pii: S0021-9150(19)30091.
    PubMed    


  81. PEREZ-CALAHORRA S, Laclaustra M, Marco-Benedi V, Lamiquiz-Moneo I, et al
    Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia.
    Atherosclerosis. 2019 Feb 12. pii: S0021-9150(19)30081.
    PubMed     Abstract available


    January 2019
  82. RODRIGUEZ-JIMENEZ C, Gomez-Coronado D, Frias Vargas M, Cerrato F, et al
    A new variant (c.1A>G) in LDLRAP1 causing autosomal recessive hypercholesterolemia: Characterization of the defect and response to PCSK9 inhibition.
    Atherosclerosis. 2019 Jan 25. pii: S0021-9150(19)30023.
    PubMed     Abstract available


  83. YAN Y, He F, Li Z, Xu R, et al
    The important role of apolipoprotein A-II in ezetimibe driven reduction of high cholesterol diet-induced atherosclerosis.
    Atherosclerosis. 2019;280:99-108.
    PubMed     Abstract available


    December 2018
  84. WAKE M, Oh A, Onishi Y, Guelfucci F, et al
    Adherence and persistence to hyperlipidemia medications in patients with atherosclerotic cardiovascular disease and those with diabetes mellitus based on administrative claims data in Japan.
    Atherosclerosis. 2018;282:19-28.
    PubMed     Abstract available


  85. SANTOS RD, Watts GF
    Simon Broome confirms that the IAS definition of severe familial hypercholesterolemia predicts coronary mortality in patients with FH.
    Atherosclerosis. 2018 Dec 22. pii: S0021-9150(18)31544.
    PubMed    


  86. VEDEL-KROGH S, Kobylecki CJ, Nordestgaard BG, Langsted A, et al
    The Christmas holidays are immediately followed by a period of hypercholesterolemia.
    Atherosclerosis. 2018;281:121-127.
    PubMed     Abstract available


  87. GUO J, Gao Y, Li X, He Y, et al
    Systematic prediction of familial hypercholesterolemia caused by low-density lipoprotein receptor missense mutations.
    Atherosclerosis. 2018;281:1-8.
    PubMed     Abstract available


  88. VUORIO A, Watts GF, Kovanen PT
    Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2018;281:25-30.
    PubMed     Abstract available


  89. LUNEGOVA OS, Mirrakhimov EM
    A familial hypercholesterolemia week in Kyrgyzstan: The joint scientific and practical symposium with the European Atherosclerosis Society (EAS), the International Atherosclerosis Society (IAS) and the Kyrgyz Society of Cardiology (KSC).
    Atherosclerosis. 2018 Dec 3. pii: S0021-9150(18)31511.
    PubMed    


    November 2018
  90. SORAN H, Adam S, Durrington PN
    Reply to: "Comments on 'Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk' ".
    Atherosclerosis. 2018 Nov 28. pii: S0021-9150(18)31508.
    PubMed    


  91. KORDONOURI O, Lange K, Boettcher I, Christoph J, et al
    New approach for detection of LDL-hypercholesterolemia in the pediatric population: The Fr1dolin-Trial in Lower Saxony, Germany.
    Atherosclerosis. 2018;280:85-91.
    PubMed     Abstract available


  92. PIRRO M, Francisci D, Bianconi V, Schiaroli E, et al
    NUtraceutical TReatment for hYpercholesterolemia in HIV-infected patients: The NU-TRY(HIV) randomized cross-over trial.
    Atherosclerosis. 2018;280:51-57.
    PubMed     Abstract available


  93. SHAH SR
    Comments on "Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk".
    Atherosclerosis. 2018 Nov 13. pii: S0021-9150(18)31476.
    PubMed    


  94. HUMPHRIES SE, Cooper JA, Capps N, Durrington PN, et al
    Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register.
    Atherosclerosis. 2018 Nov 12. pii: S0021-9150(18)31469.
    PubMed     Abstract available


  95. REESKAMP LF, Kastelein JJP, Moriarty PM, Duell PB, et al
    Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2018;280:109-117.
    PubMed     Abstract available


  96. LUIJTEN J, van Greevenbroek MMJ, Schaper NC, Meex SJR, et al
    Incidence of cardiovascular disease in familial combined hyperlipidemia: A 15-year follow-up study.
    Atherosclerosis. 2018;280:1-6.
    PubMed     Abstract available


    October 2018
  97. ALHABABI D, Zayed H
    Spectrum of mutations of familial hypercholesterolemia in the 22 Arab countries.
    Atherosclerosis. 2018;279:62-72.
    PubMed     Abstract available


  98. SHEK A, Alieva R, Kurbanov R, Hoshimov S, et al
    Burden of familial heterozygous hypercholesterolemia in Uzbekistan: Time is muscle.
    Atherosclerosis. 2018;277:524-529.
    PubMed     Abstract available


  99. MEHTA R, Martagon AJ, Galan Ramirez GA, Gonzalez Retana G, et al
    The development of the Mexican Familial Hypercholesterolemia (FH) National Registry.
    Atherosclerosis. 2018;277:517-523.
    PubMed     Abstract available


  100. AZRAII AB, Ramli AS, Ismail Z, Abdul-Razak S, et al
    Knowledge, awareness and practice regarding familial hypercholesterolaemia among primary care physicians in Malaysia: The importance of professional training.
    Atherosclerosis. 2018;277:508-516.
    PubMed     Abstract available


  101. BOTHA TC, Pilcher GJ, Wolmarans K, Blom DJ, et al
    Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies.
    Atherosclerosis. 2018;277:502-507.
    PubMed     Abstract available


  102. HAGGER MS, Hardcastle SJ, Hu M, Kwok S, et al
    Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia.
    Atherosclerosis. 2018;277:493-501.
    PubMed     Abstract available


  103. RAAL FJ, Hovingh GK, Catapano AL
    Familial hypercholesterolemia treatments: Guidelines and new therapies.
    Atherosclerosis. 2018;277:483-492.
    PubMed     Abstract available


  104. AFANASIEVA OI, Ezhov MV, Razova OA, Afanasieva MI, et al
    Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Atherosclerosis. 2018;277:477-482.
    PubMed     Abstract available


  105. PANG J, David Marais A, Blom DJ, Brice BC, et al
    Heterozygous familial hypercholesterolaemia in specialist centres in South Africa, Australia and Brazil: Importance of early detection and lifestyle advice.
    Atherosclerosis. 2018;277:470-476.
    PubMed     Abstract available


  106. SOUTO AC, Miname MH, Fukushima J, Jannes CE, et al
    Health related quality of life in individuals at high risk for familial hypercholesterolemia undergoing genetic cascade screening in Brazil.
    Atherosclerosis. 2018;277:464-469.
    PubMed     Abstract available


  107. FUTEMA M, Bourbon M, Williams M, Humphries SE, et al
    Clinical utility of the polygenic LDL-C SNP score in familial hypercholesterolemia.
    Atherosclerosis. 2018;277:457-463.
    PubMed     Abstract available


  108. ALVES AC, Benito-Vicente A, Medeiros AM, Reeves K, et al
    Further evidence of novel APOB mutations as a cause of familial hypercholesterolaemia.
    Atherosclerosis. 2018;277:448-456.
    PubMed     Abstract available


  109. HSIUNG YC, Lin PC, Chen CS, Tung YC, et al
    Identification of a novel LDLR disease-causing variant using capture-based next-generation sequencing screening of familial hypercholesterolemia patients in Taiwan.
    Atherosclerosis. 2018;277:440-447.
    PubMed     Abstract available


  110. LOPEZ G, Bernal LM, Gelvez N, Gomez LF, et al
    Mutational analysis of the LDLR gene in a cohort of Colombian families with familial hypercholesterolemia.
    Atherosclerosis. 2018;277:434-439.
    PubMed     Abstract available


  111. ALNOURI F, Athar M, Al-Allaf FA, Abduljaleel Z, et al
    Novel combined variants of LDLR and LDLRAP1 genes causing severe familial hypercholesterolemia.
    Atherosclerosis. 2018;277:425-433.
    PubMed     Abstract available


  112. BRUNHAM LR, Ruel I, Khoury E, Hegele RA, et al
    Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry.
    Atherosclerosis. 2018;277:419-424.
    PubMed     Abstract available


  113. PETRULIONIENE Z, Gargalskaite U, Kutkiene S, Staigyte J, et al
    Establishing a national screening programme for familial hypercholesterolaemia in Lithuania.
    Atherosclerosis. 2018;277:407-412.
    PubMed     Abstract available


  114. BRETT T, Qureshi N, Gidding S, Watts GF, et al
    Screening for familial hypercholesterolaemia in primary care: Time for general practice to play its part.
    Atherosclerosis. 2018;277:399-406.
    PubMed     Abstract available


  115. TRUONG TH, Kim NT, Nguyen MNT, Pang J, et al
    Homozygous familial hypercholesterolaemia in Vietnam: Case series, genetics and cascade testing of families.
    Atherosclerosis. 2018;277:392-398.
    PubMed     Abstract available


  116. GROSELJ U, Kovac J, Sustar U, Mlinaric M, et al
    Universal screening for familial hypercholesterolemia in children: The Slovenian model and literature review.
    Atherosclerosis. 2018;277:383-391.
    PubMed     Abstract available


  117. PAYNE J, Williams S, Maxwell D, Pariente MT, et al
    Familial hypercholesterolaemia patient support groups and advocacy: A multinational perspective.
    Atherosclerosis. 2018;277:377-382.
    PubMed     Abstract available


  118. DESCAMPS OS, Van Caenegem O, Hermans MP, Balligand JL, et al
    A Belgian consensus strategy to identify familial hypercholesterolaemia in the coronary care unit and its subsequent cascade screening and treatment: BEL-FaHST (The BELgium Familial Hypercholesterolaemia STrategy).
    Atherosclerosis. 2018;277:369-376.
    PubMed     Abstract available


  119. HARADA-SHIBA M, Ako J, Arai H, Hirayama A, et al
    Prevalence of familial hypercholesterolemia in patients with acute coronary syndrome in Japan: Results of the EXPLORE-J study.
    Atherosclerosis. 2018;277:362-368.
    PubMed     Abstract available


  120. VRABLIK M, Raslova K, Vohnout B, Blaha V, et al
    Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.
    Atherosclerosis. 2018;277:355-361.
    PubMed     Abstract available


  121. LATKOVSKIS G, Saripo V, Gilis D, Nesterovics G, et al
    Latvian registry of familial hypercholesterolemia: The first report of three-year results.
    Atherosclerosis. 2018;277:347-354.
    PubMed     Abstract available


  122. KAYIKCIOGLU M, Tokgozoglu L, Dogan V, Ceyhan C, et al
    What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)?
    Atherosclerosis. 2018;277:341-346.
    PubMed     Abstract available


  123. BELIARD S, Boccara F, Cariou B, Carrie A, et al
    High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry.
    Atherosclerosis. 2018;277:334-340.
    PubMed     Abstract available


  124. VAN DELDEN XM, Huijgen R, Wolmarans KH, Brice BC, et al
    LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C.
    Atherosclerosis. 2018;277:327-333.
    PubMed     Abstract available


  125. VOHNOUT B, Fabryova L, Klabnik A, Kadurova M, et al
    Treatment pattern of familial hypercholesterolemia in Slovakia: Targets, treatment and obstacles in common practice.
    Atherosclerosis. 2018;277:323-326.
    PubMed     Abstract available


  126. SCHMIDT N, Dressel A, Grammer TB, Gouni-Berthold I, et al
    Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry.
    Atherosclerosis. 2018;277:314-322.
    PubMed     Abstract available


  127. RIZOS CV, Elisaf MS, Skoumas I, Tziomalos K, et al
    Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).
    Atherosclerosis. 2018;277:308-313.
    PubMed     Abstract available


  128. DUMITRESCU A, Mosteoru S, Vinereanu D, Dan GA, et al
    Preliminary data of familial hypercholesterolemia (FH) patients in Romania.
    Atherosclerosis. 2018;277:304-307.
    PubMed     Abstract available


  129. LALIC K, Rajkovic N, Popovic L, Lukac SS, et al
    The effects of 3-year statin therapy and the achievement of LDL cholesterol target values in familial hypercholesterolemia patients: An experience from Serbia.
    Atherosclerosis. 2018;277:298-303.
    PubMed     Abstract available


  130. VALLEJO-VAZ AJ, Ray KK
    Epidemiology of familial hypercholesterolaemia: Community and clinical.
    Atherosclerosis. 2018;277:289-297.
    PubMed     Abstract available


  131. MISEREZ AR, Martin FJ, Spirk D
    DIAgnosis and Management Of familial hypercholesterolemia in a Nationwide Design (DIAMOND-FH): Prevalence in Switzerland, clinical characteristics and the diagnostic value of clinical scores.
    Atherosclerosis. 2018;277:282-288.
    PubMed     Abstract available


  132. POJSKIC L, Pojskic B
    Familial hypercholesterolemia screening program in Bosnia and Herzegovina and cardiovascular morbidity.
    Atherosclerosis. 2018;277:278-281.
    PubMed     Abstract available


  133. HARADA PH, Miname MH, Bensenor IM, Santos RD, et al
    Familial hypercholesterolemia prevalence in an admixed racial society: Sex and race matter. The ELSA-Brasil.
    Atherosclerosis. 2018;277:273-277.
    PubMed     Abstract available


  134. KUTKIENE S, Petrulioniene Z, Laucevicius A, Cerkauskiene R, et al
    Lipid profile evaluation and severe hypercholesterolaemia screening in the middle-aged population according to nationwide primary prevention programme in Lithuania.
    Atherosclerosis. 2018;277:267-272.
    PubMed     Abstract available


  135. PARAGH G, Harangi M, Karanyi Z, Daroczy B, et al
    Identifying patients with familial hypercholesterolemia using data mining methods in the Northern Great Plain region of Hungary.
    Atherosclerosis. 2018;277:262-266.
    PubMed     Abstract available


  136. CORRAL P, Geller AS, Polisecki EY, Lopez GI, et al
    Unusual genetic variants associated with hypercholesterolemia in Argentina.
    Atherosclerosis. 2018;277:256-261.
    PubMed     Abstract available


  137. VALLEJO-VAZ AJ, De Marco M, Stevens CAT, Akram A, et al
    Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).
    Atherosclerosis. 2018;277:234-255.
    PubMed     Abstract available


  138. RAY KK, Watts GF
    Improving the global care of familial hypercholesterolaemia: Starting the ball rolling.
    Atherosclerosis. 2018;277:230-233.
    PubMed    


  139. IBARRETXE D, Rodriguez-Borjabad C, Feliu A, Bilbao JA, et al
    Detecting familial hypercholesterolemia earlier in life by actively searching for affected children:The DECOPIN project.
    Atherosclerosis. 2018;278:210-216.
    PubMed     Abstract available


    September 2018
  140. OUWENEEL AB, Hoekstra M, van der Wel EJ, Schaftenaar FH, et al
    Hypercholesterolemia impairs megakaryopoiesis and platelet production in scavenger receptor BI knockout mice.
    Atherosclerosis. 2018 Sep 22. pii: S0021-9150(18)31392.
    PubMed     Abstract available


  141. JUNG KJ, Koh H, Choi Y, Lee SJ, et al
    Familial hypercholesterolemia and atherosclerotic cardiovascular mortality among Korean adults with low levels of serum cholesterol.
    Atherosclerosis. 2018;278:103-109.
    PubMed     Abstract available


  142. FARNIER M, Hovingh GK, Langslet G, Dufour R, et al
    Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program.
    Atherosclerosis. 2018 Sep 1. pii: S0021-9150(18)31345.
    PubMed     Abstract available


    August 2018
  143. SORAN H, Adam S, Durrington PN
    Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk.
    Atherosclerosis. 2018;278:135-142.
    PubMed     Abstract available


  144. BELIARD S, Gallo A, Duchene E, Carrie A, et al
    Lipoprotein-apheresis in familial hypercholesterolemia: Long-term patient compliance in a French cohort.
    Atherosclerosis. 2018;277:66-71.
    PubMed     Abstract available


  145. WALDMANN E, Vogt A, Crispin A, Altenhofer J, et al
    Corrigendum to: "Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study)" [Atherosclerosis 259 (2017 Apr) 20-25].
    Atherosclerosis. 2018;275:461-462.
    PubMed    


    July 2018
  146. MARTIN SS
    Calculating LDL cholesterol in familial combined hyperlipidemia: Out with the old, in with the new?
    Atherosclerosis. 2018 Jul 27. pii: S0021-9150(18)31241.
    PubMed    


  147. CAO YX, Liu HH, Sun D, Jin JL, et al
    The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia.
    Atherosclerosis. 2018;277:7-14.
    PubMed     Abstract available


    June 2018
  148. ADEMI Z, Martin AC
    Universal screening of children for familial hypercholesterolaemia: Value for money?
    Atherosclerosis. 2018 Jun 22. pii: S0021-9150(18)31186.
    PubMed    


  149. MEHTA R, Reyes-Rodriguez E, Yaxmehen Bello-Chavolla O, Guerrero-Diaz AC, et al
    Performance of LDL-C calculated with Martin's formula compared to the Friedewald equation in familial combined hyperlipidemia.
    Atherosclerosis. 2018 Jun 21. pii: S0021-9150(18)31180.
    PubMed     Abstract available


  150. BALLANTYNE CM, Banach M, Mancini GBJ, Lepor NE, et al
    Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
    Atherosclerosis. 2018 Jun 12. pii: S0021-9150(18)30309.
    PubMed     Abstract available


  151. MCKAY AJ, Hogan H, Humphries SE, Marks D, et al
    Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis.
    Atherosclerosis. 2018 Jun 4. pii: S0021-9150(18)30290.
    PubMed     Abstract available


    May 2018
  152. MULLER HH
    Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis: Corrections of the report on the randomized MICA-study.
    Atherosclerosis. 2018 May 30. pii: S0021-9150(18)30260.
    PubMed    


  153. WALDMANN E, Vogt A, Crispin A, Altenhofer J, et al
    Reply to: "Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis: Corrections of the report on the randomized MICA-study".
    Atherosclerosis. 2018 May 22. pii: S0021-9150(18)30261.
    PubMed    


  154. CROSLAND P, Maconachie R, Buckner S, McGuire H, et al
    Cost-utility analysis of searching electronic health records and cascade testing to identify and diagnose familial hypercholesterolaemia in England and Wales.
    Atherosclerosis. 2018;275:80-87.
    PubMed     Abstract available


  155. HUMPHRIES SE, Cooper JA, Seed M, Capps N, et al
    Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register.
    Atherosclerosis. 2018;274:41-46.
    PubMed     Abstract available


    April 2018
  156. WENG S, Kai J, Tranter J, Leonardi-Bee J, et al
    Improving identification and management of familial hypercholesterolaemia in primary care: Pre- and post-intervention study.
    Atherosclerosis. 2018;274:54-60.
    PubMed     Abstract available


    March 2018
  157. WAKE M, Onishi Y, Guelfucci F, Oh A, et al
    Treatment patterns in hyperlipidaemia patients based on administrative claim databases in Japan.
    Atherosclerosis. 2018;272:145-152.
    PubMed     Abstract available


  158. AL-SHAREA A, Murphy AJ, Huggins LA, Hu Y, et al
    SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr(-/-) type 1 diabetic mice.
    Atherosclerosis. 2018;271:166-176.
    PubMed     Abstract available


    February 2018
  159. ZHAO Y, Yang Y, Xing R, Cui X, et al
    Hyperlipidemia induces typical atherosclerosis development in Ldlr and Apoe deficient rats.
    Atherosclerosis. 2018;271:26-35.
    PubMed     Abstract available


  160. VITVEROVA B, Blazickova K, Najmanova I, Vicen M, et al
    Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta.
    Atherosclerosis. 2018;271:15-25.
    PubMed     Abstract available


  161. FOGACCI F, Cicero AFG
    Gene targeting for chylomicronemia syndrome: The brave new world.
    Atherosclerosis. 2018;269:254-255.
    PubMed    


    January 2018
  162. PELCZARSKA A, Jakubczyk M, Jakubiak-Lasocka J, Banach M, et al
    The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.
    Atherosclerosis. 2018;270:132-138.
    PubMed     Abstract available


  163. RODRIGUEZ-BORJABAD C, Ibarretxe D, Girona J, Ferre R, et al
    Lipoprotein profile assessed by 2D-1H-NMR and subclinical atherosclerosis in children with familial hypercholesterolaemia.
    Atherosclerosis. 2018;270:117-122.
    PubMed     Abstract available


  164. KAYIKCIOGLU M, Tokgozoglu L, Yilmaz M, Kaynar L, et al
    A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry).
    Atherosclerosis. 2018;270:42-48.
    PubMed     Abstract available


  165. DROUIN-CHARTIER JP, Tremblay AJ, Bergeron J, Lamarche B, et al
    High serum triglyceride concentrations in patients with homozygous familial hypercholesterolemia attenuate the efficacy of lipoprotein apheresis by dextran sulfate adsorption.
    Atherosclerosis. 2018;270:26-32.
    PubMed     Abstract available


    December 2017
  166. PEK SLT, Dissanayake S, Fong JCW, Lin MX, et al
    Spectrum of mutations in index patients with familial hypercholesterolemia in Singapore: Single center study.
    Atherosclerosis. 2017;269:106-116.
    PubMed     Abstract available


  167. SANCHEZ-HERNANDEZ RM, Prieto-Matos P, Civeira F, Lafuente EE, et al
    Autosomal recessive hypercholesterolemia in Spain.
    Atherosclerosis. 2017;269:1-5.
    PubMed     Abstract available


    October 2017
  168. HOEKE G, Wang Y, van Dam AD, Mol IM, et al
    Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis.
    Atherosclerosis. 2017;267:116-126.
    PubMed     Abstract available


  169. AMROCK SM, Duell PB, Knickelbine T, Martin SS, et al
    Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH patient registry.
    Atherosclerosis. 2017;267:19-26.
    PubMed     Abstract available


    September 2017
  170. HOVLAND A, Mundal LJ, Igland J, Veierod MB, et al
    Increased risk of heart failure and atrial fibrillation in heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2017;266:69-73.
    PubMed     Abstract available


  171. CHRISTENSEN JJ, Ulven SM, Retterstol K, Narverud I, et al
    Comprehensive lipid and metabolite profiling of children with and without familial hypercholesterolemia: A cross-sectional study.
    Atherosclerosis. 2017;266:48-57.
    PubMed     Abstract available


  172. KAWASHIRI MA, Nohara A, Higashikata T, Tada H, et al
    Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.
    Atherosclerosis. 2017;265:225-230.
    PubMed     Abstract available


    August 2017
  173. SCHMIDT N, Schmidt B, Dressel A, Gergei I, et al
    Familial hypercholesterolemia in primary care in Germany. Diabetes and cardiovascular risk evaluation: Targets and Essential Data for Commitment of Treatment (DETECT) study.
    Atherosclerosis. 2017;266:24-30.
    PubMed     Abstract available


  174. SPINA R, Cefalu' AB, Noto D, Ingrassia V, et al
    Identification of a novel LMF1 nonsense mutation responsible for severe hypertriglyceridemia by targeted next-generation sequencing.
    Atherosclerosis. 2017;263:e99.
    PubMed    


  175. ELLIS K, Pang J, Bell D, Burnett J, et al
    Elevated lipoprotein(a) and familial hypercholesterolaemia phenotypes in patients admitted to a coronary care unit with coronary artery disease.
    Atherosclerosis. 2017;263:e99.
    PubMed    


  176. MINICOCCI I, Pozzessere S, Prisco C, Montali A, et al
    Mutational analysis of children and adolescents with familial hypercholesterolemia ascertained by child-parent screening.
    Atherosclerosis. 2017;263:e99.
    PubMed    


  177. COUVERT P, Giral P, Boelle PY, Carreau V, et al
    Genetic testing of familial hypercholesterolemia: Monogenic form and polygenic contribution to cardiovascular risk.
    Atherosclerosis. 2017;263:e94.
    PubMed    


  178. GAUDET D, Gipe D, Hovingh K, Ahmad Z, et al
    Safety and efficacy of evinacumab, a monoclonal antibody to ANGPTL3, in patients with homozygous familial hypercholesterolemia: a single-arm, open-label, proof-of-concept study.
    Atherosclerosis. 2017;263:e9.
    PubMed    


  179. GHALEB Y, Elbitar S, El Khoury P, Rabes JP, et al
    Usefulness of the genetic risk score to identify phenocopies in families with autosomal dominant hypercholesterolemia?
    Atherosclerosis. 2017;263:e83.
    PubMed    


  180. VERBEEK R, Oldoni F, Boekholdt SM, Zwinderman A, et al
    Multilocus gene score or a metabolic risk score for severe hypertriglyceridemia and CVD risk prediction.
    Atherosclerosis. 2017;263:e83.
    PubMed    


  181. MUNDAL L, Igland J, Tell GS, Veierod M, et al
    Standardized incidence ratio of peripheral arterial disease and aortic stenosis in genotyped familial hypercholesterolemia in Norway during 2001-2009.
    Atherosclerosis. 2017;263:e78.
    PubMed    


  182. HUSEYNOV R, Kayikcioglu M, Bayraktaroglu S, Can L, et al
    The relationship between lipoprotein A and aortic calsification in patients with hypercholesterolemia.
    Atherosclerosis. 2017;263:e67.
    PubMed    


  183. BENEDEK P, Angelin B, Duvefelt K, Hong J, et al
    The use of genotyping as a first step in molecular diagnosis of familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e62.
    PubMed    


  184. PANG J, Abraham A, Bates TR, Bell DA, et al
    Subclinical coronary artery disease in asymptomatic patients with and without genetically confirmed familial hypercholesterolaemia.
    Atherosclerosis. 2017;263:e61-e62.
    PubMed    


  185. MEDEIROS AM, Alves AC, Bourbon M
    APOB/APOA1 ratio and APOC2 are the best biomarkers to distinguish familial hypercholesterolemia from other dyslipidaemia.
    Atherosclerosis. 2017;263:e61.
    PubMed    


  186. RYAN JD, Pang J, Watts GF, Vickery A, et al
    Using general practice electronic databases to increase the identification of familial hypercholesterolaemia in primary care.
    Atherosclerosis. 2017;263:e61.
    PubMed    


  187. RAMO J, Ripatti P, Tabassum R, Soderlund S, et al
    Mass spectrometry of circulating lipid species highlights similarity of familial hyperlipidemias and hyperlipidemias in the general population.
    Atherosclerosis. 2017;263:e61.
    PubMed    


  188. RAHMAT R, Chua YA, Ismail Z, Mohd Kasim NA, et al
    Elevated serum lipoprotein(A) concentrations in different sub-groups of clinical familial hypercholesterolaemia and their unaffected family members.
    Atherosclerosis. 2017;263:e60.
    PubMed    


  189. CHRISTENSEN JJ, Osnes L, Halvorsen B, Retterstol K, et al
    Altered leukocyte distribution under hypercholesterolemia: A cross-sectional study in children with familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e58.
    PubMed    


  190. OLIYARNYK O, Markova I, Malinska H, Trnovska J, et al
    Combination of silymarin with N-3 Polyunsaturated fatty acids enhances hepatoprotective effect of silymarin in hereditary hypertriglyceridemic rats.
    Atherosclerosis. 2017;263:e44.
    PubMed    


  191. HANDE L, Thunhaug H, Enebakk T, Ludviksen JA, et al
    Addition of polyunsaturated fatty acids to statins in familial hypercholesterolemia does not affect in vitro or in vivo endothelial function.
    Atherosclerosis. 2017;263:e43.
    PubMed    


  192. GONZALEZ-ESTRADA A, Alarcon-Garcia JC, Garcia-Ocana P, Camacho-Carrasco A, et al
    Alirocumab in patients with heterozygous familial hypercholesterolemia: Clinical experience in 27 patients at a tertiary care center in Southern Spain.
    Atherosclerosis. 2017;263:e42-e43.
    PubMed    


  193. DOWNIE P, Gritzmacher L, Palmer F, Bayly G, et al
    The variable effect of PCSK9 inhibition in patients with homozygous familial hypercholesterolaemia: Evidence to support the existence of alternative cholesterol lowering pathways.
    Atherosclerosis. 2017;263:e42.
    PubMed    


  194. PEREZ-CALAHORRA S, Plana N, Ma Sanchez-Hernandez R, Marco-Benedi V, et al
    Candidates for monoclonal antibodies to PCSK9, among heterozygous familial hypercholesterolemia patients in the dyslipidemia registry of the Spanish atherosclerosis society.
    Atherosclerosis. 2017;263:e41-e42.
    PubMed    


  195. RIPATTI P, Ramo J, Soderlund S, Surakka I, et al
    Polygenic hyperlipidemia and coronary artery disease risk.
    Atherosclerosis. 2017;263:e4.
    PubMed    


  196. LAMIQUIZ MONEO I, Baila Rueda L, Bea Sanz AM, Gallego RM, et al
    ABCG5/G8 mutations in non FH genetic hypercholesterolemias.
    Atherosclerosis. 2017;263:e39-e40.
    PubMed    


  197. BIGOLIN P, Antonucci A, Marin R, Vianello D, et al
    Genetic diagnosis of familial hypercholesterolaemia: Preliminary data from the university of padua outpatient lipid clinic.
    Atherosclerosis. 2017;263:e39.
    PubMed    


  198. HUMPHRIES S, Futema M, Cooper J, Charakida M, et al
    SEnsitivity and specificity of biochemical screening for familial hypercholesterolaemia in childhood: avon longitudinal study of parents and children (ALSPAC).
    Atherosclerosis. 2017;263:e39.
    PubMed    


  199. PETROV I, Postadzhiyan A, Tokmakova M, Addison J, et al
    Management of high and very high risk patients with familial hypercholesterolemia: Results from an observational study in Bulgaria.
    Atherosclerosis. 2017;263:e38-e39.
    PubMed    


  200. BAILA-RUEDA L, Civeira F, Lamiquiz-Moneo I, Mateo-Gallego R, et al
    Familial combined hypercholesterolemia differs from other genetic hypercholesterolemias in the hepatic cholesterol production.
    Atherosclerosis. 2017;263:e38.
    PubMed    


  201. GARCIA UG, Vicente AB, Etxebarria A, Palacios L, et al
    The leucine stretch length of PCSK9 signal peptide and its role in development of autosomal dominant hypercholesterolaemia: Unravelling the activities of P.LEU23DEL and P.LEU22_LEU23DUP variants.
    Atherosclerosis. 2017;263:e37.
    PubMed    


  202. NOHARA A, Kawashiri MA, Eto Y, Fujisaki M, et al
    Common functional variant LIPA T16P affects HDL composition among patients with heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e37-e38.
    PubMed    


  203. SIMIONESCU N, Carnuta MG, Fuior EV, Stancu CS, et al
    Targeting lipid metabolism-related genes by in vivo inhibition of MIR-486 and MIR-92A lowers plasma cholesterol levels in hyperlipidemic hamsters.
    Atherosclerosis. 2017;263:e34-e35.
    PubMed    


  204. BARALE C, Bonomo K, Noto F, Traversa M, et al
    Effects of PCSK9 inhibitors on platelet function in adults with hypercholesterolemia.
    Atherosclerosis. 2017;263:e30-e31.
    PubMed    


  205. BASSANI BORGES J, Medeiros Bastos G, Almendros Afonso TK, Da Silva Rodrigues E, et al
    Next generation sequencing in the diagnosis of familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e282.
    PubMed    


  206. SHCHERBAKOVA N, Ershova A, Zharikova A, Meshkov A, et al
    Genetics of familial hypercholesterolemia in patients recruited from epidemiological study.
    Atherosclerosis. 2017;263:e281.
    PubMed    


  207. RONEN D, Ibe UK, Shoshi S, Daniel S, et al
    Molecular genetics of familial hypercholesterolemia in Israel - revisited.
    Atherosclerosis. 2017;263:e279-e280.
    PubMed    


  208. DLOUHA D, Blaha M, Blaha V, Fatorova I, et al
    Analysis of circulating mirnas in patients with familial hypercholesterolaemia treated by LDL/Lp(a) apheresis.
    Atherosclerosis. 2017;263:e278.
    PubMed    


  209. ZHILINA S, Miramontes Gonzalez JP, Laso Guzman FJ
    Familial hypercholesterolemia and the diabetogenic effect of statins.
    Atherosclerosis. 2017;263:e264.
    PubMed    


  210. LIND L, Onnerhag K, Riserus U, Kvarnstrom M, et al
    Effects of free omega-3 carboxylic acids and fenofibrate on liver steatosis and serum lipoproteins in overweight patients with hypertriglyceridemia and non-alcoholic fatty liver disease (NAFLD).
    Atherosclerosis. 2017;263:e260.
    PubMed    


  211. RETTERSTOL K, Mundal L, Igland J, Seppola Tell G, et al
    Incidence of various types of atherosclerotic disease in patients with genotyped familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e26.
    PubMed    


  212. TICHY L, Pavlouskova J, Reblova K, Freiberger T, et al
    Autosomal dominant hypercholesterolemia in the czech republic - introduction of the next generation sequencing.
    Atherosclerosis. 2017;263:e26.
    PubMed    


  213. PAPAKONSTANTINOU P, Theodoraki E, Koulentaki M, Papadakis J, et al
    New-onset severe hypercholesterolemia in a patient with cholestatic liver disease. Should we treat the lipids?
    Atherosclerosis. 2017;263:e253-e254.
    PubMed    


  214. GROSELJ U, Kovac J, Klancar G, Pohleven S, et al
    Characteristics of children with familial and polygenic hypercholesterolemia referred through the national universal hypercholesterolemia screening - a preliminary report.
    Atherosclerosis. 2017;263:e25-e26.
    PubMed    


  215. SIMONELLI F, Miotti C, Filice BF, Gallo G, et al
    Plasmatic and phenotypic effects with alirocumab, a PCSK9 inhibitor, in familial hypercholesterolemia treatment (FH).
    Atherosclerosis. 2017;263:e246-e247.
    PubMed    


  216. GRAESDAL A, Dybvig A
    Lipoprotein apheresis as a treatment modality for familial combined hyperlipidemia (FCH) with non-alcoholic fatty liver disease (NAFLD) and coronary heart disease: a casuistic approach.
    Atherosclerosis. 2017;263:e243-e244.
    PubMed    


  217. VALLEJO-VAZ AJ, Roth EM, Hovingh GK, Lee LV, et al
    Predictive factors for alirocumab dose increase in patients with heterozygous familial hypercholesterolaemia.
    Atherosclerosis. 2017;263:e243.
    PubMed    


  218. UZOKOV J, Alyavi A, Alyavi B
    Influence of combination therapy of rosuvastatin and telmisartan on vascular and metabolic profile in hypercholesterolemic patients with metabolic syndrome.
    Atherosclerosis. 2017;263:e241.
    PubMed    


  219. YASUDA H, Fujiwara A, Komiya S, Haze T, et al
    Effects of rosuvastatin add-on treatment on hyperlipidemia in type 2 diabetic patients with chronic kidney disease receiving ethyl icosapentate.
    Atherosclerosis. 2017;263:e241-e242.
    PubMed    


  220. HUMPHRIES S, Pears R, Miedzybrodzka Z, Haralambos K, et al
    Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from FH services in the UK.
    Atherosclerosis. 2017;263:e24-e25.
    PubMed    


  221. GONZALEZ MOLERO I, Olveira G, Tinahones F
    Features of first patients treated with PCSK9 inhibitors in a specific lipid unit and effectiveness on lipid profile in familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e239.
    PubMed    


  222. GURINA N, Loukianov M, Martsevich S, Zagrebelny A, et al
    Prescription patterns of lipid-lowering therapy in patients with cardiovascular disease and hypertriglyceridemia in real clinical practice in Russia.
    Atherosclerosis. 2017;263:e237.
    PubMed    


  223. IACOCCA M, Wang J, Dron J, Robinson J, et al
    Use of next-generation sequencing to detect copy number variations in the molecular diagnosis of familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e236.
    PubMed    


  224. WU X, Pang J, Peng J, Chen Y, et al
    Effectiveness of reverse cascade screening for familial hypercholesteroleamia in very high risk families in China.
    Atherosclerosis. 2017;263:e235-e236.
    PubMed    


  225. GIAMMANCO A, Spina R, Ingrassia V, Valenti V, et al
    Genotypic and phenotypic characterization of patients with autosomal dominant hypercholesterolemia in sicily.
    Atherosclerosis. 2017;263:e235.
    PubMed    


  226. BEHESHTI S, Madsen CM, Varbo A, Nordestgaard BG, et al
    2.6-fold risk of ischemic stroke in individuals with clinical familial hypercholesterolemia: The copenhagen general population study with 102,961 individuals.
    Atherosclerosis. 2017;263:e235.
    PubMed    


  227. CASULA M, Chiodo L, Garlaschelli K, Galimberti F, et al
    Characterization of Italian patients with familial hypercholesterolemia: The lipigen study.
    Atherosclerosis. 2017;263:e235.
    PubMed    


  228. SCHWARZOVA L, Horinek A, Hubacek J, Zlatohlavek L, et al
    Mutation analysis of the LDLR gene in Czech hypercholesterolemic patients.
    Atherosclerosis. 2017;263:e234.
    PubMed    


  229. KAYA E, Kayikcioglu M, Payzin S, Can LH, et al
    Aortic elastic properties of familial hypercholesterolemia patients.
    Atherosclerosis. 2017;263:e234-e235.
    PubMed    


  230. LATKOVSKIS G, Saripo V, Gilis D, Upena-Roze A, et al
    The first results of the Latvian registry of familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e233.
    PubMed    


  231. VOHNOUT B, Fabryova L, Klabnik A, Kadurova M, et al
    Treatment pattern of familial hypercholesterolemia in slovakia: Targets, treatment and obstacles in common practice.
    Atherosclerosis. 2017;263:e233.
    PubMed    


  232. SCHMIDT N, Dressel A, Marz W
    First data from the German cascade screening program for familial hypercholesterolemia - care high.
    Atherosclerosis. 2017;263:e233-e234.
    PubMed    


  233. COCCI G, Cenci A, Bordicchia M, Sarzani R, et al
    LDLR, PCSK9, and LDLRAP1 mutations in the same patient in a familial hypercholesterolemia (FH) family.
    Atherosclerosis. 2017;263:e232.
    PubMed    


  234. ARNESEN KE, Mork I, Thorwall M, Retterstol K, et al
    Treat-to-target familial hypercholesterolemia (TTT-FH)-a prospective study of high-intensity lipid treatment in free living patients with familial hypercholesterolemia (FH).
    Atherosclerosis. 2017;263:e232-e233.
    PubMed    


  235. COHEN H, Pinhas-Hamie O, Harats D, Bitzur R, et al
    Carotid imt and plasma lipid levels among children and adolescents with familial hypercholesterolemia. A single center experience 2007-2014.
    Atherosclerosis. 2017;263:e232.
    PubMed    


  236. SEMENOVA A, Sergienko I, Ezhov M, Garcia-Giustiniani D, et al
    The presence of pathogenic mutations in patients with definite or probable diagnosis of familial hypercholesterolemia defined by targeted next generation sequencing.
    Atherosclerosis. 2017;263:e231.
    PubMed    


  237. LIN J, Wu X
    Cascade screening, clinical features and genetic aspects-familial hypercholesterolemia study in China.
    Atherosclerosis. 2017;263:e231.
    PubMed    


  238. SOLOVIEVA E, Ezhov M, Shakhnovich R, Titov V, et al
    Frequency of familial hypercholesterolemia in patients with premature acute coronary syndrome.
    Atherosclerosis. 2017;263:e230-e231.
    PubMed    


  239. TOMLINSON B, Hu M, Chan J, Mcintyre A, et al
    Severe familial hypercholesterolaemia in two brothers with three heterozygous coding mutations in LDLR.
    Atherosclerosis. 2017;263:e230.
    PubMed    


  240. TOMLINSON B, Hu M, Chan J, Mcintyre A, et al
    Severe hypertriglycerideamia related to a novel mutation in TRIB1 and a known variant in APOA5.
    Atherosclerosis. 2017;263:e230.
    PubMed    


  241. ALARCON GARCIA JC, Gonzalez Estrada A, Camacho Carrasco A, Garcia Ocana P, et al
    Combination therapy of Evolocumab and LDL apheresis in patients with heterozygous familial hypercholesterolemia: A case series.
    Atherosclerosis. 2017;263:e230.
    PubMed    


  242. REKALDE LS, Kovtsun J, Gorzelak-Pabis P, Zuszek-Frynas A, et al
    The incidence of familiar hypercholesterolemia in patients of the cardiology and internal diseases department in a Lodz hospital and their treatment analysis.
    Atherosclerosis. 2017;263:e228-e229.
    PubMed    


  243. ALVES AC, Medeiros AM, Padeira G, Ferreira AC, et al
    Sitosterolaemia: A case of rare hypercholesterolaemia in Fh patient's cohort.
    Atherosclerosis. 2017;263:e228.
    PubMed    


  244. PANG J, Abraham A, Bates TR, Bell DA, et al
    Predictors of subclinical coronary artery disease in asymptomatic patients with familial hypercholesterolaemia.
    Atherosclerosis. 2017;263:e228.
    PubMed    


  245. POJSKIC B, Stimjanin E, Pojskic L, Selimovic H, et al
    Connection between foreign body in the eye and familial hypercholesterolemia -case report.
    Atherosclerosis. 2017;263:e228.
    PubMed    


  246. SHAKHTSHNEIDER E, Orlov P, Ivanoshchuk D, Makarenkova K, et al
    Analysis of the LDLR gene variability in patients with familial hypercholesterolemia in Russia using targeted high throughput resequencing.
    Atherosclerosis. 2017;263:e227.
    PubMed    


  247. BATURINA O, Mironova O
    Clinical case of hyperlipidemia type IV in a man with diabetes, myocardial infarction and stroke.
    Atherosclerosis. 2017;263:e227-e228.
    PubMed    


  248. GRITZMACHER L, Bayly G, Honeychurch J, Williams M, et al
    The critical role of segregation analysis in determining the pathogenicity of variants of uncertain significance in patients with suspected familial hypercholesterolaemia.
    Atherosclerosis. 2017;263:e226.
    PubMed    


  249. HUBACEK JA, Adamkova V, Lanska V, Dlouha D, et al
    Polygenous hypercholesterolemia. Replication of GWAS results on Czech slavonic population.
    Atherosclerosis. 2017;263:e226-e227.
    PubMed    


  250. HUBACEK JA, Adamkova V, Vrablik M, Ceska R, et al
    Common polymorphisms as strong predictors of hypertriglyceridemia in Czech population.
    Atherosclerosis. 2017;263:e226.
    PubMed    


  251. URAZGILDEEVA S, Muzalevskaya M, Tregubov A, Nekrasova T, et al
    Main cardiovascular risk factors and HDL rather than LDL and LP(a) levels predict premature atherosclerotic cardiovascular disease in familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e226.
    PubMed    


  252. MOLLAKI V, Drogari E
    Molecular findings of monogenic familial hypercholesterolemia in the Greek population.
    Atherosclerosis. 2017;263:e225.
    PubMed    


  253. KYSELAK O, Freiberger T, Kovar J, Tichy L, et al
    Atypical phenotype of homozygous familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e224.
    PubMed    


  254. ILIC GG
    LDL cholesterol and familial hypercholesterolemia in children. Significance of familial history in detecting familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e224.
    PubMed    


  255. KHOKHLOV R, Tribuntseva L, Burlachuk V, Khokhlov L, et al
    Search strategy of familial hypercholesterolemia among hospitalized patients.
    Atherosclerosis. 2017;263:e224.
    PubMed    


  256. CHORA JR, Alves AC, Medeiros AM, Bourbon M, et al
    Systematic review of LDLR mutations associated to familial hypercholesterolaemia - evidence of functional studies and application of acmg guidelines for FH diagnosis.
    Atherosclerosis. 2017;263:e221.
    PubMed    


  257. OGURA M, Morimoto M, Harada-Shiba M
    Antioxidant property of HDL as well as cholesterol efflux capacity are independent risk markers for atherosclerotic cardiovascular disease in patients with familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e218.
    PubMed    


  258. DACLAT R, Bittar R, Salem JE, Ricaldi S, et al
    Postprandial apolipoprotein B-48 level is independent of insulin secretion in patients with moderate or severe hypertriglyceridemia.
    Atherosclerosis. 2017;263:e211.
    PubMed    


  259. OYRI LKL, Hansson P, Bogsrud MP, Narverud I, et al
    Postprandial response after intake of saturated fat compared to polyunsaturated fat in subjects with familial hypercholesterolemia and normolipidemic controls-a randomized controlled trial.
    Atherosclerosis. 2017;263:e210.
    PubMed    


  260. GRIVA E, Kyrkou K, Stamatelopoulos K, Drogari E, et al
    The effect of Lp(a) on cardiovascular function in greek pediatric population 6-16 years old. Preliminary findings in children with or without familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e207-e208.
    PubMed    


  261. SEED M, Sharifi M, Nair D, Jain A, et al
    Lipoprotein(a) level is higher inpatients with familial hypercholesterolaemia than in normal healthy subjects, contribution of variants in the LPA gene.
    Atherosclerosis. 2017;263:e207.
    PubMed    


  262. POLYPATHELLI I, Demosthenous C, Gavra M, Matsaridou E, et al
    Hypertriglyceridemia-induced acute pancreatitis in third trimester of pregnancy: A case report.
    Atherosclerosis. 2017;263:e203-e204.
    PubMed    


  263. BENIMETSKAYA K, Ragino Y, Shakhtshneider E, Makarenkova K, et al
    Proprotein convertase subtilisin/kexin type 9 (PCSK9) level in patients with familial hypercholesterolemia in Russia.
    Atherosclerosis. 2017;263:e195.
    PubMed    


  264. ERSHOVA A, Meshkov A, Bazhan S, Storozhok M, et al
    The prevalence of heterozygous familial hypercholesterolemia in the Russian Federation: A substudy of the ESSE-Rf.
    Atherosclerosis. 2017;263:e184-e185.
    PubMed    


  265. FARES AL, Hussein El Bacha AA, Souza CS, Garcia De Carvalho JA, et al
    High prevalence of familial hypercholesterolemia in patients with coronary heart disease at a Brazilian quaternary healthcare center.
    Atherosclerosis. 2017;263:e181-e183.
    PubMed    


  266. SCICALI R, Platania R, Purrazzo G, Giannone A, et al
    Screening for unknown hypercholesterolemia in a hospital population: A model for preventive medicine.
    Atherosclerosis. 2017;263:e181.
    PubMed    


  267. ALVES R, Yamaya A, Souza A, Rosa R, et al
    Identification of patients with familial hypercholesterolemia in dyslipidemia ambulatory of public hospital.
    Atherosclerosis. 2017;263:e179.
    PubMed    


  268. IYENGAR S, Gupta R, Ravi S
    Looking for a needle in a haystack? Familial hypercholesterolemia in coronary artery disease.
    Atherosclerosis. 2017;263:e177.
    PubMed    


  269. DUMITRESCU A, Mosteoru S, Gaita D, Mut G, et al
    The prevalence of familial hypercholesterolemia in children from Timisoara.
    Atherosclerosis. 2017;263:e170-e171.
    PubMed    


  270. SANZ AMB, Jarauta E, Perez-Calahorra S, Marco-Benedi V, et al
    Association between carotid plaque and coronary events in subjects with genetic hypercholesterolemia.
    Atherosclerosis. 2017;263:e17-e18.
    PubMed    


  271. GOCMEN AY, Gumuslu S
    Atorvastatin influences oxidative stress markers in hypercholesterolemic rats.
    Atherosclerosis. 2017;263:e162.
    PubMed    


  272. ALYAHYA AM, Al Masri A, Eleter E, Alhersi A, et al
    Progranulin attenuates in vivo acute myocardial ischemia/reperfusion injury in a rat model of hypercholesterolemia.
    Atherosclerosis. 2017;263:e148-e149.
    PubMed    


  273. FUSTER JJ, Maclauchlan S, Zuriaga MA, Polackal MN, et al
    Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis in hyperlipidemic mice.
    Atherosclerosis. 2017;263:e14.
    PubMed    


  274. KRITIKOU E, Van Der Heijden T, Maarten S, Van Duijn J, et al
    Hypercholesterolemia induces a mast cell-CD4+ T-cell interaction in atherosclerosis.
    Atherosclerosis. 2017;263:e124.
    PubMed    


  275. MOREGOLA A, Bonacina F, Coe D, Pellegatta F, et al
    LDLR influence on CD4 T cells differentiation in mice and in familial hypercholesterolemia patients.
    Atherosclerosis. 2017;263:e115.
    PubMed    


  276. MACCHI C, Botta M, Bosisio R, Pavanello C, et al
    Efficacy and safety of a nutraceutical with probiotic and red yeast rice extract in patients with moderate hypercholesterolemia: A randomized, double-blind, placebo-controlled study.
    Atherosclerosis. 2017;263:e109.
    PubMed    


  277. OGURA M, Furuhashi M, Morimoto M, Matsumoto M, et al
    Fatty acid-binding protein 5 as a residual risk for atherosclerotic cardiovascular disease in patients with familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e100.
    PubMed    


    July 2017
  278. NIKKOLA E, Ko A, Alvarez M, Cantor RM, et al
    Family-specific aggregation of lipid GWAS variants confers the susceptibility to familial hypercholesterolemia in a large Austrian family.
    Atherosclerosis. 2017;264:58-66.
    PubMed     Abstract available


  279. YANG ZH, Gordon SM, Sviridov D, Wang S, et al
    Dietary supplementation with long-chain monounsaturated fatty acid isomers decreases atherosclerosis and alters lipoprotein proteomes in LDLr(-/-) mice.
    Atherosclerosis. 2017;262:31-38.
    PubMed     Abstract available


  280. STEINHAGEN-THIESSEN E, Stroes E, Soran H, Johnson C, et al
    The role of registries in rare genetic lipid disorders: Review and introduction of the first global registry in lipoprotein lipase deficiency.
    Atherosclerosis. 2017;262:146-153.
    PubMed     Abstract available


    June 2017
  281. SUDO M, Li Y, Hiro T, Takayama T, et al
    Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: Serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits.
    Atherosclerosis. 2017 Jun 23. pii: S0021-9150(17)31169.
    PubMed     Abstract available


  282. SILVA PRS, Jannes CE, Oliveira TGM, Miname MH, et al
    Evaluation of clinical and laboratory parameters used in the identification of index cases for genetic screening of familial hypercholesterolemia in Brazil.
    Atherosclerosis. 2017;263:257-262.
    PubMed     Abstract available


  283. BERBEE JFP, Mol IM, Milne GL, Pollock E, et al
    Deuterium-reinforced polyunsaturated fatty acids protect against atherosclerosis by lowering lipid peroxidation and hypercholesterolemia.
    Atherosclerosis. 2017 Jun 21. pii: S0021-9150(17)31165.
    PubMed     Abstract available


  284. SANTOS RD, Miname MH
    Increased subclinical atherosclerosis burden in familial hypercholesterolemia phenotype: What do genetic defects tell us and what are the clinical implications?
    Atherosclerosis. 2017 Jun 12. pii: S0021-9150(17)30254.
    PubMed    


  285. VONGPROMEK R, Bos S, Ten Kate GR, Bujo H, et al
    Soluble LR11 associates with aortic root calcification in asymptomatic treated male patients with familial hypercholesterolemia.
    Atherosclerosis. 2017 Jun 9. pii: S0021-9150(17)30268.
    PubMed     Abstract available


  286. BEA AM, Perez-Calahorra S, Marco-Benedi V, Lamiquiz-Moneo I, et al
    Effect of intensive LDL cholesterol lowering with PCSK9 monoclonal antibodies on tendon xanthoma regression in familial hypercholesterolemia.
    Atherosclerosis. 2017;263:92-96.
    PubMed     Abstract available


  287. TERAMOTO T, Daida H, Ikewaki K, Arai H, et al
    Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia.
    Atherosclerosis. 2017;261:69-77.
    PubMed     Abstract available


  288. WELTEN SMJ, de Jong RCM, Wezel A, de Vries MR, et al
    Inhibition of 14q32 microRNA miR-495 reduces lesion formation, intimal hyperplasia and plasma cholesterol levels in experimental restenosis.
    Atherosclerosis. 2017;261:26-36.
    PubMed     Abstract available


  289. ARAI H, Yamashita S, Yokote K, Araki E, et al
    Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipida
    Atherosclerosis. 2017;261:144-152.
    PubMed     Abstract available


  290. OUWENEEL AB, van der Sluis RJ, Nahon JE, Van Eck M, et al
    Simvastatin treatment aggravates the glucocorticoid insufficiency associated with hypocholesterolemia in mice.
    Atherosclerosis. 2017;261:99-104.
    PubMed     Abstract available


    May 2017
  291. HAGENSEN MK, Mortensen MB, Kjolby M, Stillits NL, et al
    Type 1 diabetes increases retention of low-density lipoprotein in the atherosclerosis-prone area of the murine aorta.
    Atherosclerosis. 2017;263:7-14.
    PubMed     Abstract available


  292. SHARIFI M, Higginson E, Bos S, Gallivan A, et al
    Greater preclinical atherosclerosis in treated monogenic familial hypercholesterolemia vs. polygenic hypercholesterolemia.
    Atherosclerosis. 2017 May 13. pii: S0021-9150(17)30218.
    PubMed     Abstract available


  293. MASANA L, Plana N, Perez-Calahorra S, Ibarretxe D, et al
    How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Atherosclerosis. 2017;262:107-112.
    PubMed     Abstract available


  294. BUONUOMO PS, Iughetti L, Pisciotta L, Rabacchi C, et al
    Timely diagnosis of sitosterolemia by next generation sequencing in two children with severe hypercholesterolemia.
    Atherosclerosis. 2017;262:71-77.
    PubMed     Abstract available


  295. OTHMAN RA, Myrie SB, Mymin D, Roullet JB, et al
    Effect of ezetimibe on low- and high-density lipoprotein subclasses in sitosterolemia.
    Atherosclerosis. 2017;260:27-33.
    PubMed     Abstract available


    April 2017
  296. MANGILI LC, Miname MH, Silva PRS, Bittencourt MS, et al
    Achilles tendon xanthomas are associated with the presence and burden of subclinical coronary atherosclerosis in heterozygous familial hypercholesterolemia: A pilot study.
    Atherosclerosis. 2017 Apr 30. pii: S0021-9150(17)30189.
    PubMed     Abstract available


  297. BOURBON M, Alves AC, Alonso R, Mata N, et al
    Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia: The SAFEHEART registry.
    Atherosclerosis. 2017;262:8-13.
    PubMed     Abstract available


    March 2017
  298. LI S, Wu NQ, Zhu CG, Zhang Y, et al
    Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease.
    Atherosclerosis. 2017;260:67-74.
    PubMed     Abstract available


  299. FUTEMA M, Cooper JA, Charakida M, Boustred C, et al
    Screening for familial hypercholesterolaemia in childhood: Avon Longitudinal Study of Parents and Children (ALSPAC).
    Atherosclerosis. 2017;260:47-55.
    PubMed     Abstract available


    February 2017
  300. WALDMANN E, Vogt A, Crispin A, Altenhofer J, et al
    Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study).
    Atherosclerosis. 2017;259:20-25.
    PubMed     Abstract available


  301. JANUS ED
    Homozygous familial hypercholesterolaemia - Early recognition and early treatment improve outcomes.
    Atherosclerosis. 2017 Feb 16. pii: S0021-9150(17)30060.
    PubMed    


  302. XIANG R, Fan LL, Lin MJ, Li JJ, et al
    The genetic spectrum of familial hypercholesterolemia in the central south region of China.
    Atherosclerosis. 2017;258:84-88.
    PubMed     Abstract available


  303. LADWIG KH, Baumert J, Marten-Mittag B, Lukaschek K, et al
    Room for depressed and exhausted mood as a risk predictor for all-cause and cardiovascular mortality beyond the contribution of the classical somatic risk factors in men.
    Atherosclerosis. 2017;257:224-231.
    PubMed     Abstract available


    January 2017
  304. WIDHALM K, Benke IM, Fritz M, Geiger H, et al
    Homozygous familial hypercholesterolemia: Summarized case reports.
    Atherosclerosis. 2017;257:86-89.
    PubMed     Abstract available


  305. BRUCKERT E, Kalmykova O, Bittar R, Carreau V, et al
    Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France.
    Atherosclerosis. 2017;257:130-137.
    PubMed     Abstract available


  306. BOS S, Duvekot MH, Ten Kate GR, Verhoeven AJ, et al
    Carotid artery plaques and intima medial thickness in familial hypercholesteraemic patients on long-term statin therapy: A case control study.
    Atherosclerosis. 2017;256:62-66.
    PubMed     Abstract available


    December 2016
  307. DURST R, Ibe UK, Shpitzen S, Schurr D, et al
    Molecular genetics of familial hypercholesterolemia in Israel-revisited.
    Atherosclerosis. 2016;257:55-63.
    PubMed     Abstract available


  308. PANES O, Gonzalez C, Hidalgo P, Valderas JP, et al
    Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin.
    Atherosclerosis. 2016;257:164-171.
    PubMed     Abstract available


  309. CHRISTENSEN JJ, Osnes LT, Halvorsen B, Retterstol K, et al
    Altered leukocyte distribution under hypercholesterolemia: A cross-sectional study in children with familial hypercholesterolemia.
    Atherosclerosis. 2016;256:67-74.
    PubMed     Abstract available


  310. BOOT C, Holmes E, Neely RD
    Serum non-HDL cholesterol to apolipoprotein B ratio as a screening test for familial dysbetalipoproteinaemia (Type III hyperlipidaemia) in patients with mixed hyperlipidaemia.
    Atherosclerosis. 2016;255:7.
    PubMed    


  311. HARALAMBOS K, Ashfield-Watt P, Edwards R, Gingell R, et al
    Five year experience of scoring criteria for familial hypercholesterolaemia (FH) genetic testing in wales: Should the criteria be refined to include age?
    Atherosclerosis. 2016;255:7-8.
    PubMed    


  312. HONEYCHURCH J, Watson E, Hills A, Dean P, et al
    Validation and utility of a new NGS assay for familial hypercholesterolaemia incorporating 12 LDL-C-raising SNPs.
    Atherosclerosis. 2016;255:6-7.
    PubMed    


  313. GOYALE A, Jain A, Sharifi M, Gallivan A, et al
    Validation of low density lipoprotein correction factors in a multi-ethnic familial hypercholesterolaemia population at a North London lipid clinic.
    Atherosclerosis. 2016;255:6.
    PubMed    


  314. SHARIFI M, Jain A, Persaud J, Humphries SE, et al
    Cardiovascular biomarkers in monogenic familial hypercholesterolaemia and polygenic hypercholesterolaemia.
    Atherosclerosis. 2016;255:4.
    PubMed    


  315. HILLS A, Honeychurch J, Davies J, Robinson C, et al
    4 years' cascade genetic testing for familial hypercholesterolaemia in England - Increased referrals and ascertainment.
    Atherosclerosis. 2016;255:3.
    PubMed    


  316. KATE HARALAMBOS K, Whitmore J
    Using pass database and geographic information systems (GIS) to map familial hypercholesterolaemia (FH) diagnoses in England and Wales.
    Atherosclerosis. 2016;255:3.
    PubMed    


  317. LUNGLEY J, Jayne Z, Harvey D, Nair DR, et al
    Early identification of familial hypercholesterolaemIa (FH): The prevention of Cardiovascular disease (CVD).
    Atherosclerosis. 2016;255:3.
    PubMed    


  318. GRITZMACHER L, Bayly GR, Williams M, Hills A, et al
    The critical importance of segregation analysis in the management of patients and their families with suspected familial hypercholesterolaemia: 3 examples from the bristol FH clinic.
    Atherosclerosis. 2016;255:2-3.
    PubMed    


  319. COZENS A, McMahon S, Purves J, Miedzybrodska Z, et al
    Detection, assessment and treatment of children with familial hypercholesterolaemia in Scotland.
    Atherosclerosis. 2016;255:2.
    PubMed    


  320. GELLATLY E
    Familial hypercholesterolaemia (FH) - Finding the needle in a haystack in a Scottish population.
    Atherosclerosis. 2016;255:2.
    PubMed    


  321. ASHFIELD-WATT P, Haralambos K, Edwards R, Townsend D, et al
    Estimation of the prevalence of cholesteryl ester storage disorder (CESD) in a cohort of patients with clinical features of familial hypercholesterolaemia.
    Atherosclerosis. 2016;255:1.
    PubMed    


    November 2016
  322. FRANCE M, Rees A, Datta D, Thompson G, et al
    HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom.
    Atherosclerosis. 2016 Nov 5. pii: S0021-9150(16)31420.
    PubMed     Abstract available


    October 2016
  323. SETIA N, Saxena R, Arora A, Verma IC, et al
    Spectrum of mutations in homozygous familial hypercholesterolemia in India, with four novel mutations.
    Atherosclerosis. 2016;255:31-36.
    PubMed     Abstract available


  324. DANCER M, Caussy C, Di Filippo M, Moulin P, et al
    Lack of evidence for a liver or intestinal miRNA regulation involved in the hypertriglyceridemic effect of APOC3 3'UTR variant SstI.
    Atherosclerosis. 2016;255:6-10.
    PubMed     Abstract available


  325. CASULA M, Scotti L, Tragni E, Merlino L, et al
    Drug treatment and adherence of subjects <40 years with diagnosis of heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2016;254:172-178.
    PubMed     Abstract available


  326. OGURA M, Makino H, Kamiya C, Yoshimatsu J, et al
    Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: Seven case series and discussion.
    Atherosclerosis. 2016;254:179-183.
    PubMed     Abstract available


    September 2016
  327. KOSTNER K
    Coronary calcification in familial hypercholesterolemia: Not all about LDL.
    Atherosclerosis. 2016 Sep 28. pii: S0021-9150(16)31377.
    PubMed    


  328. MARTIN R, Latten M, Hart P, Murray H, et al
    Genetic diagnosis of familial hypercholesterolaemia using a rapid biochip array assay for 40 common LDLR, APOB and PCSK9 mutations.
    Atherosclerosis. 2016;254:8-13.
    PubMed     Abstract available


  329. MANGILI LC, Mangili OC, Bittencourt MS, Miname MH, et al
    Epicardial fat is associated with severity of subclinical coronary atherosclerosis in familial hypercholesterolemia.
    Atherosclerosis. 2016;254:73-77.
    PubMed     Abstract available


  330. ARCA M
    Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
    Atherosclerosis. 2016 Sep 2. pii: S0021-9150(16)31315.
    PubMed     Abstract available


    May 2016
  331. NARDIN M, Verdoia M, Schaffer A, Barbieri L, et al
    Vitamin D status, diabetes mellitus and coronary artery disease in patients undergoing coronary angiography.
    Atherosclerosis. 2016;250:114-121.
    PubMed     Abstract available


  332. BANERJEE Y, Santos RD, Al-Rasadi K, Rizzo M, et al
    Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?
    Atherosclerosis. 2016;248:62-75.
    PubMed     Abstract available


    March 2016
  333. CAUSSY C, Charriere S, Meirhaeghe A, Dallongeville J, et al
    Multiple microRNA regulation of lipoprotein lipase gene abolished by 3'UTR polymorphisms in a triglyceride-lowering haplotype harboring p.Ser474Ter.
    Atherosclerosis. 2016;246:280-6.
    PubMed     Abstract available


  334. POKHAREL Y, Steinberg L, Chan W, Akeroyd JM, et al
    Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline.
    Atherosclerosis. 2016;246:115-20.
    PubMed     Abstract available


  335. SCHWEITZER M, Makhoul S, Paliouras M, Beitel LK, et al
    Characterization of the NPC1L1 gene and proteome from an exceptional responder to ezetimibe.
    Atherosclerosis. 2016;246:78-86.
    PubMed     Abstract available


    January 2016
  336. ZHENG L, Wu T, Zeng C, Li X, et al
    SAP deficiency mitigated atherosclerotic lesions in ApoE(-/-) mice.
    Atherosclerosis. 2016;244:179-87.
    PubMed     Abstract available


  337. FARNIER M, Jones P, Severance R, Averna M, et al
    Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
    Atherosclerosis. 2016;244:138-46.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hyperlipoproteinemias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: